Halozyme Therapeutics/ US40637H1095 /
29/05/2024 21:59:56 | Chg. -0.03 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
42.77USD | -0.07% | 30,198 Turnover: 1.28 mill. |
-Bid Size: - | -Ask Size: - | 42.87 | 42.09 |
GlobeNewswire
06/05
The Benchmark Company Announces Upcoming Healthcare House Call VIRTUAL One-on-One Investor Conferenc...
GlobeNewswire
06/11/2023
Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develo...
GlobeNewswire
22/02/2022
Arcutis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
GlobeNewswire
02/09/2021
Crinetics Pharmaceuticals Expands Executive Team with Addition of Jeff Knight as Chief Operating Off...
GlobeNewswire
30/06/2021
TRACON Pharmaceuticals Announces Appointment of Ya Huang as Executive Director of Statistical Progra...
GlobeNewswire
26/05/2021
Novome Biotechnologies Appoints Dr. David N. Cook and Zachary Hornby to its Board of Directors
GlobeNewswire
12/05/2021
Medicenna Appoints Immuno-Oncology Expert Dr. Mann Muhsin as Chief Medical Officer
GlobeNewswire
22/09/2020
Genmab Commences Binding Arbitration of Two Matters Under License Agreement with Janssen
GlobeNewswire
02/07/2019
Madrigal Pharmaceuticals Announces Appointment of Jim Daly to Board of Directors
GlobeNewswire
11/06/2019
Iovance Biotherapeutics Appoints Athena Countouriotis, M.D., to Board of Directors
GlobeNewswire
28/02/2019
FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers
GlobeNewswire
15/02/2019
Consolidated Research: 2019 Summary Expectations for Tenaris S.A, Rapid7, Halozyme Therapeutics, Car...
GlobeNewswire
04/02/2019
argenx and Halozyme enter global collaboration and license agreement for ENHANZE® technology
GlobeNewswire
27/12/2018
Factors of Influence in 2019, Key Indicators and Opportunity within Halozyme Therapeutics, Capricor ...
GlobeNewswire
11/12/2018
Biopharmaceutical Drug Delivery Device Technology - Global Markets to 2023: Trends & Developments